RU2020125266A - Составы конъюгата антитело против egfr-лекарственное средство - Google Patents
Составы конъюгата антитело против egfr-лекарственное средство Download PDFInfo
- Publication number
- RU2020125266A RU2020125266A RU2020125266A RU2020125266A RU2020125266A RU 2020125266 A RU2020125266 A RU 2020125266A RU 2020125266 A RU2020125266 A RU 2020125266A RU 2020125266 A RU2020125266 A RU 2020125266A RU 2020125266 A RU2020125266 A RU 2020125266A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- cancer
- adc
- egfr
- formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 53
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title claims 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title claims 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title claims 4
- 229940079593 drug Drugs 0.000 title claims 2
- 239000003814 drug Substances 0.000 title claims 2
- 238000009472 formulation Methods 0.000 claims 14
- 150000001413 amino acids Chemical group 0.000 claims 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 6
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 6
- 239000004094 surface-active agent Substances 0.000 claims 6
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 229930006000 Sucrose Natural products 0.000 claims 5
- 108010059074 monomethylauristatin F Proteins 0.000 claims 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 5
- 229920000136 polysorbate Polymers 0.000 claims 5
- 229950008882 polysorbate Drugs 0.000 claims 5
- 229920000053 polysorbate 80 Polymers 0.000 claims 5
- 229940068968 polysorbate 80 Drugs 0.000 claims 5
- 239000005720 sucrose Substances 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010047741 Vulval cancer Diseases 0.000 claims 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 239000013011 aqueous formulation Substances 0.000 claims 2
- 108010044540 auristatin Proteins 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 125000000185 sucrose group Chemical group 0.000 claims 2
- 201000005102 vulva cancer Diseases 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
- A61K39/39525—Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790490P | 2013-03-15 | 2013-03-15 | |
| US61/790,490 | 2013-03-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015144287A Division RU2015144287A (ru) | 2013-03-15 | 2014-03-14 | Составы конъюгата антитело против egfr-лекарственное средство |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020125266A true RU2020125266A (ru) | 2020-09-24 |
Family
ID=50680154
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020125266A RU2020125266A (ru) | 2013-03-15 | 2014-03-14 | Составы конъюгата антитело против egfr-лекарственное средство |
| RU2015144287A RU2015144287A (ru) | 2013-03-15 | 2014-03-14 | Составы конъюгата антитело против egfr-лекарственное средство |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015144287A RU2015144287A (ru) | 2013-03-15 | 2014-03-14 | Составы конъюгата антитело против egfr-лекарственное средство |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20140286969A1 (OSRAM) |
| EP (2) | EP3517132A1 (OSRAM) |
| JP (4) | JP6382935B2 (OSRAM) |
| KR (4) | KR102305226B1 (OSRAM) |
| CN (2) | CN110433139A (OSRAM) |
| AU (4) | AU2014228172B2 (OSRAM) |
| BR (1) | BR112015023391A8 (OSRAM) |
| CA (1) | CA2906130A1 (OSRAM) |
| CY (1) | CY1121949T1 (OSRAM) |
| DK (1) | DK2968588T3 (OSRAM) |
| ES (1) | ES2727134T3 (OSRAM) |
| HK (1) | HK1219044A1 (OSRAM) |
| HR (1) | HRP20190672T1 (OSRAM) |
| HU (1) | HUE044071T2 (OSRAM) |
| IL (2) | IL241009A0 (OSRAM) |
| LT (1) | LT2968588T (OSRAM) |
| ME (1) | ME03457B (OSRAM) |
| MX (2) | MX2015012549A (OSRAM) |
| NZ (1) | NZ630826A (OSRAM) |
| PL (1) | PL2968588T3 (OSRAM) |
| PT (1) | PT2968588T (OSRAM) |
| RS (1) | RS58666B1 (OSRAM) |
| RU (2) | RU2020125266A (OSRAM) |
| SG (2) | SG11201507430RA (OSRAM) |
| SI (1) | SI2968588T1 (OSRAM) |
| TR (1) | TR201905313T4 (OSRAM) |
| TW (3) | TW201945032A (OSRAM) |
| WO (1) | WO2014143765A1 (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9707302B2 (en) * | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| WO2012100346A1 (en) | 2011-01-24 | 2012-08-02 | Ym Biosciences Inc. | Antibodies selective for cells presenting egfr at high density |
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| CA2942101A1 (en) | 2014-03-21 | 2015-09-24 | Abbvie Inc. | Anti-egfr antibodies and antibody drug conjugates |
| KR101628872B1 (ko) | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | 자가-희생 기를 포함하는 화합물 |
| EP3223857A4 (en) * | 2014-10-31 | 2018-06-27 | Formation Biologics Inc. | Egfr antibody-based combination therapy |
| US10195175B2 (en) * | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| WO2017051249A1 (en) | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
| WO2017051254A1 (en) * | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-egfr antibody drug conjugates |
| KR102847348B1 (ko) | 2015-11-25 | 2025-08-19 | 주식회사 리가켐바이오사이언스 | 펩타이드 그룹을 포함하는 접합체 및 이와 관련된 제조방법 |
| US11173214B2 (en) | 2015-11-25 | 2021-11-16 | Legochem Biosciences, Inc. | Antibody-drug conjugates comprising branched linkers and methods related thereto |
| SI3380124T1 (sl) | 2015-11-25 | 2024-10-30 | Legochem Biosciences, Inc. | Konjugati, ki obsegajo samožrtvujoče skupine in z njimi povezani postopki |
| MX2018014175A (es) * | 2016-05-17 | 2020-02-07 | Abbvie Biotherapeutics Inc | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. |
| BR112018075645A2 (pt) * | 2016-06-08 | 2019-04-09 | Abbvie Inc. | conjugados de anticorpo fármaco anti-egfr |
| CA3027498A1 (en) * | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| AU2018246806B2 (en) | 2017-03-29 | 2022-05-12 | Ligachem Biosciences Inc. | Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof |
| US20200129633A1 (en) * | 2017-06-06 | 2020-04-30 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof |
| TWI880888B (zh) * | 2017-08-23 | 2025-04-21 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製劑及其冷凍乾燥方法 |
| KR102816741B1 (ko) | 2017-08-31 | 2025-06-04 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 개량 제조 방법 |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| EP3790591A4 (en) | 2018-05-09 | 2022-05-11 | LegoChem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
| EP3849538A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| US20210347915A1 (en) * | 2018-09-20 | 2021-11-11 | Phasebio Pharmaceuticals, Inc. | Methods of reversing ticagrelor activity |
| CN110960490A (zh) * | 2018-09-28 | 2020-04-07 | 江苏恒瑞医药股份有限公司 | 一种抗egfr抗体偶联药物组合物及其用途 |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| MX2021010414A (es) * | 2019-03-04 | 2021-09-14 | Amgen Inc | Reversibilidad in vivo de especies de alto peso molecular. |
| ES2967128T3 (es) * | 2019-03-26 | 2024-04-26 | Remegen Co Ltd | Preparación farmacéutica de conjugado de anticuerpo anti-Her2 y fármaco |
| CN111939267B (zh) * | 2019-05-17 | 2024-12-20 | 百奥泰生物制药股份有限公司 | 抗体-药物偶联物制剂、制备方法及应用 |
| AU2019341066B1 (en) * | 2019-08-07 | 2021-04-01 | Mabplex International Co., Ltd. | Antibody-drug conjugates and uses thereof |
| KR20210028544A (ko) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
| CN112516090B (zh) * | 2019-09-18 | 2023-06-20 | 上海复旦张江生物医药股份有限公司 | 抗体偶联药物的药物组合、冷冻干燥剂及制备方法、用途 |
| EP4129345A4 (en) * | 2020-03-25 | 2023-11-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBODY-DRUG CONJUGATE AND USE THEREOF |
| BR112022020595A2 (pt) * | 2020-04-10 | 2023-01-17 | Lantern Pharma Inc | Métodos hidroxiureametil-acilfulveno para tratamento de câncer do cérebro ou câncer do snc. |
| CN116761632A (zh) * | 2020-11-11 | 2023-09-15 | 加图立大学校产学协力团 | 用于增强靶向治疗剂的治疗效果的基于抗体的缀合物 |
| WO2022103170A1 (ko) * | 2020-11-11 | 2022-05-19 | 가톨릭대학교 산학협력단 | 표적 치료제의 치료 효과 증진을 위한 항체 기반 컨쥬게이트 |
| KR102683876B1 (ko) * | 2020-11-11 | 2024-07-11 | 가톨릭대학교 산학협력단 | 표적 치료제의 치료 효과 증진을 위한 항체 기반 컨쥬게이트 |
| US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| CN115300623B (zh) * | 2021-05-08 | 2024-06-21 | 盛禾(中国)生物制药有限公司 | 抗egfr融合蛋白或其抗原结合片段的组合物及其用途 |
| US20230027739A1 (en) | 2021-05-10 | 2023-01-26 | Entrada Therapeutics, Inc. | Antigen-binding and antigen degradation constructs |
| CN115721732B (zh) * | 2021-08-27 | 2025-03-07 | 上海复旦张江生物医药股份有限公司 | 抗体偶联药物的药物组合物、制剂及其制备方法、用途 |
| EP4429654A4 (en) | 2021-11-09 | 2025-07-09 | Univ Case Western Reserve | PSMA-TARGETED CONJUGATE COMPOUNDS AND THEIR USES |
| CN114740108B (zh) * | 2022-03-28 | 2023-07-14 | 天津键凯科技有限公司 | 一种聚合物修饰抗体类药物的修饰度的测定方法 |
| IL317567A (en) * | 2022-06-10 | 2025-02-01 | Acelyrin Inc | ANTI-IGF-1R antibody compounds |
| US20250367311A1 (en) * | 2022-06-15 | 2025-12-04 | Shanghai Hansoh Biomedical Co., Ltd. | Pharmaceutical composition containing an antibody-drug conjugate and use thereof |
| EP4353220A1 (en) * | 2022-10-12 | 2024-04-17 | Pierre Fabre Medicament | Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate |
| AU2024210908A1 (en) | 2023-01-18 | 2025-08-21 | Tyligand Bioscience (Shanghai) Limited | Antibody-drug conjugate and use thereof |
| TW202523354A (zh) * | 2023-11-29 | 2025-06-16 | 大陸商四川科倫博泰生物醫藥股份有限公司 | 抗體製劑 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4563304A (en) | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
| US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| DE68921982D1 (de) | 1988-06-14 | 1995-05-04 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
| US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
| US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| WO1992018619A1 (en) | 1991-04-10 | 1992-10-29 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| AU2238292A (en) | 1991-06-14 | 1993-01-12 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
| ES2166368T3 (es) * | 1993-12-24 | 2002-04-16 | Merck Patent Gmbh | Inmunoconjugados. |
| EP1231268B1 (en) | 1994-01-31 | 2005-07-27 | Trustees Of Boston University | Polyclonal antibody libraries |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
| US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| WO1998036765A1 (en) | 1997-02-25 | 1998-08-27 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
| US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| SI2357006T1 (sl) | 2002-07-31 | 2016-01-29 | Seattle Genetics, Inc. | Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni |
| AU2003282624A1 (en) | 2002-11-14 | 2004-06-03 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| US20050023292A1 (en) * | 2003-02-14 | 2005-02-03 | Rubbermaid Commercial Products Llc | Liquid dispenser |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
| EP1740954B1 (en) * | 2004-04-07 | 2015-08-19 | Genentech, Inc. | Mass spectrometry of antibody conjugates |
| CN101065151B (zh) * | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| SI3248613T1 (sl) | 2005-07-18 | 2022-04-29 | Seagen Inc. | Konjugati beta-glukuronidni linker-zdravilo |
| US8158590B2 (en) | 2005-08-05 | 2012-04-17 | Syntarga B.V. | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation |
| SG178602A1 (en) * | 2009-09-01 | 2012-04-27 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US20110076232A1 (en) | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| NZ602054A (en) * | 2010-03-17 | 2014-10-31 | Abbott Res Bv | Anti-nerve growth factor (ngf) antibody compositions |
| SG185366A1 (en) * | 2010-05-04 | 2012-12-28 | Merrimack Pharmaceuticals Inc | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| KR20150132864A (ko) * | 2013-03-15 | 2015-11-26 | 애브비 인코포레이티드 | 항체 약물 접합체(adc) 정제 |
| JP7011392B2 (ja) * | 2014-02-18 | 2022-01-26 | イラミーナ インコーポレーテッド | Ｄｎａプロファイリングのための方法および組成物 |
-
2014
- 2014-03-14 US US14/211,954 patent/US20140286969A1/en not_active Abandoned
- 2014-03-14 SG SG11201507430RA patent/SG11201507430RA/en unknown
- 2014-03-14 HK HK16106793.8A patent/HK1219044A1/zh unknown
- 2014-03-14 PT PT14722450T patent/PT2968588T/pt unknown
- 2014-03-14 WO PCT/US2014/027868 patent/WO2014143765A1/en not_active Ceased
- 2014-03-14 TR TR2019/05313T patent/TR201905313T4/tr unknown
- 2014-03-14 RU RU2020125266A patent/RU2020125266A/ru unknown
- 2014-03-14 SG SG10201707633VA patent/SG10201707633VA/en unknown
- 2014-03-14 CN CN201910492831.8A patent/CN110433139A/zh active Pending
- 2014-03-14 KR KR1020157029907A patent/KR102305226B1/ko not_active Expired - Fee Related
- 2014-03-14 TW TW108107373A patent/TW201945032A/zh unknown
- 2014-03-14 TW TW103109817A patent/TWI689313B/zh not_active IP Right Cessation
- 2014-03-14 BR BR112015023391A patent/BR112015023391A8/pt active Search and Examination
- 2014-03-14 SI SI201431167T patent/SI2968588T1/sl unknown
- 2014-03-14 CA CA2906130A patent/CA2906130A1/en not_active Abandoned
- 2014-03-14 JP JP2016502649A patent/JP6382935B2/ja not_active Expired - Fee Related
- 2014-03-14 KR KR1020227034264A patent/KR20220139443A/ko not_active Withdrawn
- 2014-03-14 EP EP18211172.4A patent/EP3517132A1/en not_active Withdrawn
- 2014-03-14 MX MX2015012549A patent/MX2015012549A/es active IP Right Grant
- 2014-03-14 NZ NZ630826A patent/NZ630826A/en not_active IP Right Cessation
- 2014-03-14 LT LTEP14722450.5T patent/LT2968588T/lt unknown
- 2014-03-14 ES ES14722450T patent/ES2727134T3/es active Active
- 2014-03-14 RS RS20190452A patent/RS58666B1/sr unknown
- 2014-03-14 HU HUE14722450A patent/HUE044071T2/hu unknown
- 2014-03-14 DK DK14722450.5T patent/DK2968588T3/en active
- 2014-03-14 KR KR1020227009445A patent/KR20220041957A/ko not_active Withdrawn
- 2014-03-14 CN CN201480025078.7A patent/CN105163763B/zh not_active Expired - Fee Related
- 2014-03-14 EP EP14722450.5A patent/EP2968588B1/en active Active
- 2014-03-14 PL PL14722450T patent/PL2968588T3/pl unknown
- 2014-03-14 RU RU2015144287A patent/RU2015144287A/ru not_active Application Discontinuation
- 2014-03-14 TW TW110106528A patent/TW202146054A/zh unknown
- 2014-03-14 HR HRP20190672TT patent/HRP20190672T1/hr unknown
- 2014-03-14 ME MEP-2019-102A patent/ME03457B/me unknown
- 2014-03-14 AU AU2014228172A patent/AU2014228172B2/en not_active Ceased
- 2014-03-14 KR KR1020217029935A patent/KR20210118238A/ko not_active Withdrawn
-
2015
- 2015-09-01 IL IL241009A patent/IL241009A0/en unknown
- 2015-09-11 MX MX2020000333A patent/MX2020000333A/es unknown
-
2018
- 2018-08-02 JP JP2018145641A patent/JP2018184468A/ja active Pending
- 2018-11-23 AU AU2018267662A patent/AU2018267662A1/en not_active Abandoned
-
2019
- 2019-04-09 CY CY20191100397T patent/CY1121949T1/el unknown
- 2019-10-17 US US16/655,716 patent/US20200282072A1/en not_active Abandoned
-
2020
- 2020-05-24 IL IL274881A patent/IL274881A/en unknown
- 2020-06-03 JP JP2020096643A patent/JP2020143152A/ja active Pending
- 2020-11-25 AU AU2020277164A patent/AU2020277164A1/en not_active Abandoned
-
2022
- 2022-06-20 JP JP2022098605A patent/JP2022126754A/ja active Pending
-
2023
- 2023-01-27 AU AU2023200432A patent/AU2023200432A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020125266A (ru) | Составы конъюгата антитело против egfr-лекарственное средство | |
| JP2016515511A5 (OSRAM) | ||
| HRP20201186T1 (hr) | Konjugati protutijela protiv cmet s lijekom i postupci njihove upotrebe | |
| CN102812045B (zh) | 用于治疗或预防人表皮生长因子受体‑3(her‑3)相关疾病的材料和方法 | |
| HRP20191335T1 (hr) | Anti-egfrviii antitijela i njihove primjene | |
| HRP20230941T1 (hr) | Anti-tigit antitijela i postupci njihove primjene | |
| JP2017160208A5 (OSRAM) | ||
| RU2013155695A (ru) | Препараты антител против с-мет | |
| RU2014151359A (ru) | Высококонцентрированные составы моноклональных антител | |
| RU2013128444A (ru) | Новые модуляторы и способы их применения | |
| CN113271942A (zh) | 抗体-药物缀合物与parp抑制剂的组合 | |
| JP2014514346A5 (OSRAM) | ||
| JP2019514998A5 (OSRAM) | ||
| JP2015534579A5 (OSRAM) | ||
| JP2016502504A5 (OSRAM) | ||
| HRP20240167T1 (hr) | Formulacije ljudskih anti-rankl protutijela i postupci njihove upotrebe | |
| RU2017132432A (ru) | Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками flt3 | |
| JP2017510559A5 (OSRAM) | ||
| RU2020124944A (ru) | Антитела против egfr и конъюгаты антитело-лекарственное средство | |
| JP2020509027A5 (OSRAM) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2013512920A5 (OSRAM) | ||
| US11167039B2 (en) | MET antibody drug conjugates | |
| IL311145B2 (en) | Antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| JP2016508973A5 (OSRAM) |